


PHARMACEUTICAL 2022

Altimmune Inc. Rank 133 of 466



RealRate

PHARMACEUTICAL 2022

Altimmune Inc. Rank 133 of 466

The relative strengths and weaknesses of Altimmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimmune Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Altimmune Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 27% points.

The company's Economic Capital Ratio, given in the ranking table, is 206%, being 128% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	204,126
Cost of Goods Sold	0
Intangible Assets	12,419
Liabilities, Current	18,276
Liabilities, Non-Current	0
Other Assets	872
Other Compr. Net Income	4.4
Other Expenses	11,370
Other Liabilities	1,454
Other Net Income	-177
Other Revenues	4,410
Property and Equipment	1,448
Research and Development	74,541
Selling, General and Administrative Expense	15,413

Output Variable	Value in 1000 USD
Assets	218,865
Liabilities	19,730
Expenses	101,324
Revenues	4,410
Stockholders Equity	199,135
Net Income	-97,091
Comprehensive Net Income	-97,089
Economic Capital Ratio	206%

